Clinical Trials on Hormone-resistant Prostate Cancer in South Africa
Total 890 results
-
Atridia Pty Ltd.CompletedProstate Cancer | NeoplasmAustralia
-
National Cancer Institute (NCI)Eastern Cooperative Oncology Group; Southwest Oncology GroupCompletedLow, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate CancerProstate CancerUnited States, South Africa
-
Medical University of South CarolinaRecruitingProstate Cancer Recurrent | Solid Tumor, AdultUnited States
-
Medical University of South CarolinaTerminated
-
Medical University of South CarolinaWithdrawnProstate CancerUnited States
-
University of South CarolinaUnited States Department of DefenseCompleted
-
Medical University of South CarolinaWithdrawn
-
Medical University of South CarolinaCompleted
-
Royal North Shore HospitalCompleted
-
St George Hospital, AustraliaRecruiting
-
Royal North Shore HospitalUniversity of SydneyCompleted
-
Progen PharmaceuticalsAventis Pharmaceuticals; Northern Sydney and Central Coast Area Health ServiceCompleted
-
SanofiCompleted
-
Biotech Equity Partners Pty LtdUnknownProstate CancerAustralia
-
Royal North Shore HospitalWithdrawn
-
University of SydneyTrans Tasman Radiation Oncology GroupUnknownProstate CancerAustralia
-
Royal North Shore HospitalCompletedCancer of the ProstateAustralia
-
BayerCompletedBone Metastases | Hormone Refractory Prostate CancerItaly, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedStage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | PSA Level Five to Ten | PSA Level Less Than Five | PSA Level Ten to FiftyUnited States
-
AstraZenecaActive, not recruitingHormone-Sensitive Prostate CancerUnited States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more
-
Centers for Disease Control and PreventionThe University of Texas Health Science Center, HoustonCompletedProstate CancerUnited States
-
Noxopharm LimitedCompletedCancerNew Zealand, Georgia, Australia
-
Medical University of South CarolinaTerminatedProstate CancerUnited States
-
SanofiTerminated
-
AstraZenecaCompletedNon-Metastatic Prostate CancerCzech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
-
Australian and New Zealand Urogenital and Prostate...Endocyte; Movember Foundation; Australian Nuclear Science and Technology Organisation... and other collaboratorsCompletedMetastatic Cancer | Cancer of the ProstateAustralia
-
Novartis PharmaceuticalsRecruitingOligometastatic Prostate Cancer (OMPC)Japan, Singapore, Canada, Israel, Switzerland, Australia, United States
-
M.D. Anderson Cancer CenterUnknownProstate CancerUnited States
-
DendreonCompletedMetastatic Prostate CancerUnited States
-
BayerActive, not recruitingMetastatic Hormone-sensitive Prostate CancerUnited States
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingMetastatic Hormone Sensitive Prostate CancerKorea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
-
Impact Therapeutics, Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Primary Peritoneal Cancer | Advanced Solid TumoursAustralia
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Macquarie University, AustraliaUnknown
-
Centocor, Inc.TerminatedCancer, ProstateUnited States, United Kingdom, Belgium, Germany, Spain, France, Austria
-
Janssen Research & Development, LLCActive, not recruitingCastration-Resistant Prostatic CancerUnited States, China, Italy, Korea, Republic of, Taiwan, Australia, Sweden, Belgium, Canada, France, Hungary, Israel, Malaysia, Russian Federation, Portugal, Germany, Bulgaria, Spain, Netherlands, Turkey, United Kingdom, Ukraine, Po... and more
-
Lawson Health Research InstituteCompletedProstate CancerUnited Kingdom, Australia, Canada
-
Calvary Mater Newcastle, AustraliaAbbottCompleted
-
Eli Lilly and CompanySarah Cannon Development InnovationsCompletedProstate Cancer MetastaticUnited States
-
US Oncology ResearchPfizerCompleted
-
Christopher Sweeney, MBBSSanofi; Hoosier Cancer Research Network; Walther Cancer InstituteTerminatedMetastatic Prostate CancerUnited States, Canada
-
Ferring PharmaceuticalsCompletedProstate CancerNetherlands, Belgium, Germany, Russian Federation, South Africa, Hungary, Romania, Poland
-
University of Texas Southwestern Medical CenterCompletedProstate CancerUnited States
-
Sensei Biotherapeutics, Inc.AccelovanceCompleted
-
Bavarian NordicCompletedProstate Cancer MetastaticUnited States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
-
ImunonCompletedProstate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)SuspendedProstate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8Canada, United States
-
Movember FoundationKing's College London; Centre hospitalier de l'Université de Montréal (CHUM); University of California, San Francisco and other collaboratorsActive, not recruitingINTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4) (INTERVAL)Metastatic Prostate CancerUnited States, Australia, Netherlands, Canada, United Kingdom, Germany, Ireland
-
US Oncology ResearchEli Lilly and Company; Oregon Health and Science UniversityCompletedAndrogen-independent Prostate CancerUnited States